Amy Laverdiere is the program lead for MDMA at MAPS Public Benefit Corporation. Amy has spent her career in many areas of drug and medical device development and commercialization. Prior to joining MAPS PBC, Amy was the program lead for PALFORZIA, the first FDA-approved therapy for peanut allergy, at Aimmune Therapeutics. She previously worked in process development at Genzyme and Genentech, in finance at Hatteras Venture partners, and held various marketing and commercial development roles at Medtronic and Cytokinetics. Amy holds a bachelor's degree in chemical engineering from the Massachusetts Institute of Technology and an MBA from Duke University's Fuqua School of Business.